摘要：

本发明涉及LY6G6F,VSIG10,TMEM25以及LSR蛋白,它们是免疫疗法,癌症,感染性失调,和/或免疫相关失调的治疗,以及药物开发的适合的靶标. The present invention relates to LY6G6F, VSIG10, TMEM25 and LSR proteins, they are immune therapy, cancers, infectious disorders, and / or treatment of immune-related disorders, as well as for drug development target. 本发明进一步涉及可溶性LY6G6F,VSIG10,TMEM25以及LSR分子,LY6G6F,VSIG10,TMEM25以及LSR的细胞外结构域和偶联物,它们是针对免疫疗法,癌症,感染性失调,和/或免疫相关失调的治疗的适合的药物. The present invention further relates to a soluble LY6G6F, VSIG10, TMEM25 and LSR molecule, LY6G6F, VSIG10, TMEM25 and LSR extracellular domain and conjugates, which are for immunotherapy, cancer, infectious disorders, and / or immune-related disorders suitable pharmaceutical treatments. 本发明进一步涉及特异性针对LY6G6F,VSIG10,TMEM25或LSR分子的抗体和抗原结合片段以及包含它们的偶联物,和/或替代性支架,它们是针对免疫疗法,癌症,感染性失调,和/或免疫相关失调的治疗的适合的药物. The present invention further relates to specific for LY6G6F, VSIG10, TMEM25 LSR molecule or antibody and antigen-binding fragments thereof, and conjugates containing them, and / or alternative stent, which is directed immunotherapy, cancer, infectious disorders, and / or suitable pharmaceutical treatment of immune-related disorders.

展开